Visium Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Visium Asset Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-250,000	Closed	-$2.95M	–	796
2015 Q3	$2.95M	Hold	250,000	–	–	0.04%	386
2015 Q2	$4.88M	Buy	+250,000	New	+$5.19M	0.07%	289

Other funds holding PLX

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Visium Asset Management's PLX Position: Q4 2015 in Review

Visium Asset Management sold out of Protalix BioTherapeutics (PLX) in Q4 2015, closing a stake of 250,000 shares — an estimated $2.95M sold.

Visium Asset Management first reported a position in PLX in Q2 2015 and held it in 2 quarters. The position peaked at $4.88M in Q2 2015. 31 funds tracked by Wall St. Rank hold PLX as of Q4 2015.

Visium Asset Management reported no remaining Protalix BioTherapeutics position as of Q4 2015 after selling out during the quarter.
Visium Asset Management sold 250,000 Protalix BioTherapeutics shares in Q4 2015, an estimated $2.95M.
Visium Asset Management first reported a position in Protalix BioTherapeutics in Q2 2015 and held it in 2 quarters.
Visium Asset Management's Protalix BioTherapeutics position peaked at $4.88M in Q2 2015.
31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.